Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy

Journal of Clinical Oncology

Volumn 28, Issue 16, 2010, Pages 2690-2697

  Chlebowski, Rowan T ^a   Anderson, Garnet ^a   Manson, JoAnn E ^a   Pettinger, Mary ^a   Yasmeen, Shagufta ^a   Lane, Dorothy ^a   Langer, Robert D ^a   Hubbell, F Allan ^a   McTiernan, Anne ^a   Hendrix, Susan ^a   Schenken, Robert ^a   Stefanick, Marcia L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; WOMEN'S HEALTH; AGE DISTRIBUTION; AREA UNDER THE CURVE; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ESTROGEN THERAPY; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INCIDENCE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEEDLE BIOPSY; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL RATE; TIME;

AGE DISTRIBUTION; AGED; AREA UNDER CURVE; BIOPSY, NEEDLE; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; ROC CURVE; SURVIVAL RATE; TIME FACTORS;

EID: 77954935319     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.8799     Document Type: Article

References (29)

1. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002 (Pubitemid 34761611)
2. Chlebowski RT, Hendrix SL, Langer RD, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 289:3243-3253, 2003 (Pubitemid 37430077)
3. Hersh AL, Stefanick ML, Stafford RS: National use of postmenopausal hormone therapy. JAMA 291:47-53, 2004
4. Ravdin PM, Cronin KA, Howlander B, et al: The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674, 2007
5. Kim N, Gross C, Curtis J, et al: The impact of clinical trials on the use of hormone replacement therapy: A population based study. J Gen Intern Med 20:1026-1031, 2005 (Pubitemid 41726657)
6. Chlebowski RT, Kuller LH, Prentice RL, et al: Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573-587, 2009
7. Chlebowski RT, Anderson G, Pettinger M, et al: Estrogen plus progestin and breast cancer detection with mammography and breast biopsy. Arch Intern Med 168:370-377, 2008 (Pubitemid 351347128)
8. Stefanick ML, Anderson GL, Margolis K, et al: Effects of conjugated equine estrogens on breast cancer and mammography in postmenopausal women with hysterectomy. JAMA 295:1647-1657, 2006
9. Anderson GL, Manson J, Wallace R, et al: Implementation of the Women's Health Initiative study design. Ann Epidemiol 13:S5-S17, 2003 (suppl) (Pubitemid 37324175)
10. Hays J, Hunt JR, Hubbel A, et al: The Women's Health Initiative recruitment methods and results. Ann Epidemiol 13:S18-S77, 2003 (suppl) (Pubitemid 37324176)
11. Anderson GL, Limacher M, Assaf AR, et al: Effects of conjugated equine estrogen on postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712, 2004 (Pubitemid 38489892)
12. Yasmeen S, Romano PS, Pettinger M, et al: Frequency and predictive value of mammographic recommendation for short-interval follow-up. J Natl Cancer Inst 95:429-436, 2003 (Pubitemid 36432417)
13. American College of Radiology: BI-RADS Mammography (ed 4). http://www.acr.org/SecondaryMainMenuCategories/quality-safety/BIRADSAtlas/BIRAD
14. Curb JD, McTiernan A, Heckberr SR, et al: Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 13:S122-S128, 2003 (suppl) (Pubitemid 37324181)
15. National Cancer Institute: Surveillance Epidemiology and End Results, 2006. http://seer.cancer.gov/
16. Anderson GL, Kooperberg C, Geller N, et al: Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. Clinical Trials 4:207-217, 2007 (Pubitemid 47400529)
17. Pepe MS: The Statistical Evaluation of Medical Tests for Classification and Prediction. New York, NY, Oxford University Press, 2003
18. Kavanagh AM, Cawson J, Byrnes GB, et al: Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidemiol Biomarkers Prev 14:1060-1064, 2005 (Pubitemid 40656448)
19. Chiarelli AM, Kirsh VA, Klar NS, et al: Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol Biomarkers Prev 15:1856-1862, 2006
20. Banks E: Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: A review. J Med Screen 8:29-34, 2001
21. Carney PA, Miglioretti DL, Yankaskas BC, et al: Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138:168-175, 2003 (Pubitemid 36231622)
22. Laya MB, Larson EB, Taplin SH, et al: Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 88:643-649, 1996 (Pubitemid 26152550)
23. Thurfjell E, Holmberg L, Persson I: Screening mammography: Sensitivity and specificity in relation to hormone replacement therapy. Radiology 203:339-341, 1997 (Pubitemid 27176202)
24. Banks E, Reeves G, Beral V, et al: Hormone replacement therapy and false positive recall in the Million Women Study: Patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res 8:R8, 2006
25. Ginsburg OM, Martin LJ, Boyd NF: Mammographic density, lobular involution, and risk of breast cancer. Br J Cancer 99:1369-1374, 2008
26. McTiernan A, Chlebowski RT, Martin C, et al: Conjugated equine estrogen influence on mammographic density in postmenopausal women in the Women's Health Initiative Randomized Trial. J Clin Oncol 27:6135-6143, 2009
27. McTiernan A, Martin CF, Peck JD, et al: Estrogen plus progestin use and mammographic density in postmenopausal women: Women's Health Initiative Randomized Trial. J Natl Cancer Inst 97:1366-1376, 2005 (Pubitemid 41487804)
28. Feig SA: Auditing and benchmarks in screening and diagnostic mammography. Radiol Clin North Am 45:791-800, vi, 2007
29. Breast Cancer Surveillance Consortium: NCI-funded Breast Cancer Surveillance Consortium cooperative agreement (U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731, U01CA70040). http://breastscreening.cancer.gov/data/benchmarks/diagnostic/table6.html